The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2025 | What is the optimal length of chemotherapy in pancreatic ductal adenocarcinoma?
Michele Reni, MD, IRCCS San Raffaele Scientific Institute, Milan, Italy, comments on the administration of chemotherapy in patients with pancreatic ductal adenocarcinoma (PDAC), recommending that they complete all six cycles if possible, with exceptions made for those experiencing toxicity, psychological fatigue, or other limitations. Dr Reni suggests that completing the full course of chemotherapy before surgery is ideal when feasible. This interview took place at the European Society for Medical Oncology (ESMO) 2025 Congress in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Nowadays, what I advise, what I suggest to my patients is to continue, if possible, to receive all the six cycles. So we stop chemotherapy before six cycles in those patients who are unable to continue because of toxicity or because of psychological fatigue or for other reasons. But if we can, we continue the whole run of chemo before surgery.
This transcript is AI-generated...
Nowadays, what I advise, what I suggest to my patients is to continue, if possible, to receive all the six cycles. So we stop chemotherapy before six cycles in those patients who are unable to continue because of toxicity or because of psychological fatigue or for other reasons. But if we can, we continue the whole run of chemo before surgery.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
